ABG
EWTX icon

Ally Bridge Group’s Edgewise Therapeutics EWTX Stock Holding History

Ally Bridge Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-250,000
Closed -$6.2M – 30
2025
Q4 		$6.2M Buy
+250,000
New +$5.02M 6.46% 8

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ally Bridge Group's EWTX Position: Q2 2026 in Review

Ally Bridge Group reduced its Edgewise Therapeutics (EWTX) stake by 48% in Q2 2026, selling an estimated $2.68M and leaving 83,300 shares worth $3.38M. The position accounts for 2.99% of the portfolio, ranked #9.

Ally Bridge Group first reported a position in EWTX in Q3 2024 and has held it in 6 quarters since. The position peaked at $5.07M in Q1 2026. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Ally Bridge Group held 83,300 shares of Edgewise Therapeutics worth $3.38M as of Q2 2026.
  • Ally Bridge Group sold 77,700 Edgewise Therapeutics shares in Q2 2026, an estimated $2.68M.
  • Edgewise Therapeutics made up 2.99% of Ally Bridge Group's portfolio in Q2 2026, its #9 holding.
  • Ally Bridge Group first reported a position in Edgewise Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Ally Bridge Group's Edgewise Therapeutics position peaked at $5.07M in Q1 2026.
  • 227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.